Over the last decade, multiple myeloma treatment options have evolved from double, to triple to quadruple combination therapies. What do these new options mean for patients, and how will treatment change in the future? C. Ola Landgren, M.D., Ph.D., will address these questions and more June 3, at the 2024 annual meeting of the American Society of Clinical Oncology (ASCO).